GEN Exclusives

More »

BioMarket Trends

More »
Apr 1, 2010 (Vol. 30, No. 7)

Molecular Diagnostic Market Heating Up

Growth Being Driven by Sequencing Advances and the Personalized Medicine Quest

  • Click Image To Enlarge +
    Molecular diagnostics is intricately linked to a number of other technologies.

    The scope of the molecular diagnostic market is much wider than usually realized, which tends to skew market estimates. Many reports that attempt to estimate the size of the molecular diagnostic market fall short because new technologies, including biomarkers, copy number variation, and DNA sequencing, which are integral to the category, are overlooked.

    The worldwide molecular diagnostic market, including peripheral technologies, in vitro and in vivo diagnostics, and molecular imaging, was worth $9 billion in 2009. It is estimated that the market will expand to $15.5 billion in 2014 and $42.5 billion in 2019. New technologies have been responsible for 15 years of steady growth in the sector. 

    Apart from the market value in dollars, another growth indicator has been an increase in the number of major players involved in the sector. The number of companies actively involved in developing molecular diagnostics increased from less than 100 in 1995 to over 500 in 2010.

    Overlap in several molecular diagnostic technologies makes it difficult to divide the market more precisely. The complex relationship between molecular diagnostics and other technologies is shown in the Figure.

    DNA sequencing, which is currently used mostly in research with emerging applications in drug discovery and molecular diagnostics, is one of the most promising contributors to growth in the molecular diagnostic sector. DNA sequencing and molecular diagnostics are intricately linked  to the concept of personalized medicine.

    Genomic medicine, a component of personalized medicine, suggests that the sequencing of the human genome will enable healthcare to enter an era in which an individual patient’s genome will help determine the optimal approach to care, whether it is preventive, diagnostic, or therapeutic. Personalized genome sequencing, as a result, will likely become an integral part of personalized medicine in the near future.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?